Immunome CBO exercises options, sells 1,092 shares
Immunome Inc. chief business officer Horn Kinney reported an option exercise and share sale.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Immunome Inc. chief business officer Horn Kinney reported an option exercise and share sale. On the same day, Kinney exercised employee stock options to acquire 1,092 shares of common stock at $12.92 per share and sold 1,092 shares at $25.00 per share in an open-market transaction.
The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on March 30, 2026. Following these transactions, Kinney reported no directly held common shares and 128,908 employee stock options remaining, exercisable at $12.92 and expiring on August 8, 2034.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,092 shares ($13K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Horn Kinney
Role
CHIEF BUSINESS OFFICER
Sold
1,092 shs ($27K)
Approx. gross sale proceeds
$27K
Approx. exercise cost
$14K
Approx. pre-tax spread
$13K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 1,092 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,092 | $12.92 | $14K |
| Sale | Common Stock | 1,092 | $25.00 | $27K |
Holdings After Transaction:
Employee Stock Option (right to buy) — 128,908 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (2)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026.
- F2. 25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years.
Key Figures
Shares sold: 1,092 shares
Sale price: $25.00 per share
Shares exercised: 1,092 shares
+5 more
8 metrics
Shares sold
1,092 shares
Open-market sale of Immunome common stock
Sale price
$25.00 per share
Price for 1,092 Immunome common shares sold
Shares exercised
1,092 shares
Employee stock options exercised into common stock
Option exercise price
$12.92 per share
Exercise price of employee stock options
Options remaining
128,908 options
Employee stock options held after transactions
Option expiration
August 8, 2034
Expiration date of remaining options at $12.92
Direct common shares after
0 shares
Directly held Immunome common stock post-transaction
10b5-1 plan adoption date
March 30, 2026
Date Horn Kinney adopted trading plan
Key Terms
Rule 10b5-1 trading plan, Employee Stock Option (right to buy), open-market sale, vested
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 30, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Option (right to buy) financial
"Employee Stock Option (right to buy) with 1,092.0000 underlying shares of Common Stock at a $12.9200 conversion or exercise price."
open-market sale financial
"transaction_action: open-market sale, transaction_code_description: Sale in open market or private transaction."
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vested financial
"25% of the shares subject to the option vested on August 9, 2025, and the remaining shares will vest monthly thereafter over three years."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Immunome (IMNM) disclose in this Form 4?
Immunome reported that chief business officer Horn Kinney exercised employee stock options and sold common shares. He acquired 1,092 shares through option exercise and sold 1,092 shares in an open-market transaction on the same date.
What stock options did Horn Kinney exercise in the Immunome (IMNM) Form 4?
Kinney exercised employee stock options for 1,092 shares at a $12.92 exercise price. These options relate to Immunome common stock and were part of a larger option grant that continues to vest over time.
Does Horn Kinney still hold Immunome (IMNM) stock options after this transaction?
Yes. After the transaction, Kinney reported holding 128,908 employee stock options. These options carry a $12.92 exercise price, relate to Immunome common stock, and are scheduled to expire on August 8, 2034.
Was the Immunome (IMNM) insider sale made under a Rule 10b5-1 plan?
Yes. The Form 4 states the sales were made under a Rule 10b5-1 trading plan. The trading plan was adopted by Horn Kinney on March 30, 2026, indicating the transactions were pre-arranged rather than discretionary.
How do Horn Kinney’s Immunome (IMNM) options vest over time?
According to the Form 4, 25% of the option shares vested on August 9, 2025. The remaining option shares are scheduled to vest in equal monthly installments over three years following that initial vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates